Syantra Patents

Patent portfolio assigned to Syantra (verified via public assignee records). Calgary precision-biotech, RNA/gene-expression liquid biopsy (Onco-ID / Syantra DX) for early breast cancer detection. Patent filing completed Oct 2024 plus expanded patent-pending IP portfolio; exact count not disclosed. Partners are clinical-study sites and foundations, not paying customers.